These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 25350685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1.
    Fatima S, Bathini R, Sivan SK, Manga V.
    J Recept Signal Transduct Res; 2012 Aug; 32(4):214-24. PubMed ID: 22713102
    [Abstract] [Full Text] [Related]

  • 8. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C, Halder AK, Adhikari N, Saha A, Saha KD, Gayen S, Jha T.
    Eur J Med Chem; 2015 Jan 27; 90():860-75. PubMed ID: 25535952
    [Abstract] [Full Text] [Related]

  • 9. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
    Choubey SK, Jeyaraman J.
    J Mol Graph Model; 2016 Nov 27; 70():54-69. PubMed ID: 27668885
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Exploring the effect of PARP-1 flexibility in docking studies.
    Antolin AA, Carotti A, Nuti R, Hakkaya A, Camaioni E, Mestres J, Pellicciari R, Macchiarulo A.
    J Mol Graph Model; 2013 Sep 27; 45():192-201. PubMed ID: 24056306
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
    Salmas RE, Unlu A, Yurtsever M, Noskov SY, Durdagi S.
    J Enzyme Inhib Med Chem; 2016 Sep 27; 31(1):112-20. PubMed ID: 26083304
    [Abstract] [Full Text] [Related]

  • 15. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
    Kaur M, Silakari O.
    J Biomol Struct Dyn; 2017 Nov 27; 35(14):3043-3060. PubMed ID: 27678281
    [Abstract] [Full Text] [Related]

  • 16. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB, Aguan K, Mitra S, Bhattacharjee A.
    J Biomol Struct Dyn; 2017 Jun 27; 35(8):1729-1742. PubMed ID: 27410776
    [Abstract] [Full Text] [Related]

  • 17. 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
    Gohlke BO, Overkamp T, Richter A, Richter A, Daniel PT, Gillissen B, Preissner R.
    BMC Bioinformatics; 2015 Sep 24; 16():308. PubMed ID: 26403354
    [Abstract] [Full Text] [Related]

  • 18. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
    Qiu Y, Zhou L, Hu Y, Bao Y.
    J Recept Signal Transduct Res; 2019 Apr 24; 39(2):154-166. PubMed ID: 31355691
    [Abstract] [Full Text] [Related]

  • 19. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations.
    Dong L, Feng R, Bi J, Shen S, Lu H, Zhang J.
    J Mol Model; 2018 Mar 06; 24(4):86. PubMed ID: 29511885
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.